zelenectide pevedotin — Conference presentation
H2 2026
Report initial data for Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer at a scientific conference in the second half of 2026.Source filing
BCYC biotech catalysts & pipeline
BICYCLE THERAPEUTICS PLC · Data as of 2026-10-25